Atossa Genetics (NASDAQ:ATOS) Issues Earnings Results

Key Points

• Atossa Genetics reported a quarterly loss of ($0.07) earnings per share, missing the consensus estimate by ($0.01).
• The company’s stock price has seen significant movement, with a 52-week low of $0.55 and a high of $1.66, and it currently trades at $0.77.
• Bank of America Corp DE increased its stake in Atossa Genetics by 51.3%, highlighting growing institutional interest in the stock.

Atossa Genetics (NASDAQ:ATOS - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.01), Zacks reports.

Atossa Genetics Price Performance

NASDAQ ATOS traded up $0.01 on Tuesday, hitting $0.77. 592,120 shares of the stock were exchanged, compared to its average volume of 880,867. The business's fifty day moving average is $0.85 and its 200 day moving average is $0.80. Atossa Genetics has a 52 week low of $0.55 and a 52 week high of $1.66. The company has a market capitalization of $99.46 million, a PE ratio of -3.65 and a beta of 0.92.

Hedge Funds Weigh In On Atossa Genetics

A hedge fund recently raised its stake in Atossa Genetics stock. Bank of America Corp DE lifted its position in shares of Atossa Genetics Inc. (NASDAQ:ATOS - Free Report) by 51.3% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 111,475 shares of the company's stock after buying an additional 37,809 shares during the quarter. Bank of America Corp DE owned about 0.09% of Atossa Genetics worth $105,000 as of its most recent SEC filing. 12.74% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have weighed in on ATOS shares. Craig Hallum raised Atossa Genetics to a "strong-buy" rating and set a $4.00 price objective for the company in a report on Thursday, June 5th. Ascendiant Capital Markets lifted their price objective on Atossa Genetics from $7.25 to $7.50 and gave the company a "buy" rating in a report on Friday, June 6th.

Atossa Genetics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.